|  |  |  | FDG-SUVmax | FMISO-TBR | ||||
---|---|---|---|---|---|---|---|---|---|
Variables | Â | Number | (%) | Mean | SD | p Value | Mean | SD | p Value |
Number of patients | Â | 44 | Â | Â | Â | Â | Â | Â | Â |
Age, years | Average | 53.5 | Â | Â | Â | Â | Â | Â | Â |
(range) | (38–78) |  |  |  |  |  |  |  | |
< 50 | 20 | (45.4) | 11.1 | 4.4 | 0.02 | 1.3 | 0.4 | 0.3 | |
≥ 50 | 24 | (45.5) | 7.9 | 4.2 | 1.2 | 0.4 | |||
Tumor size | Average | 40.9 | Â | Â | Â | Â | Â | Â | Â |
(range) | (14–80) |  |  |  |  |  |  |  | |
< 4 cm | 25 | (56.8) | 8 | 3.6 | 0.02 | 1.1 | 0.4 | 0.03 | |
≥ 4 cm | 19 | (43.1) | 11.1 | 5.1 | 1.4 | 0.4 | |||
Histology | IDC | 41 | (93.1) | 9.6 | 4.4 | 0.1 | 1.2 | 0.4 | 0.9 |
Others | 3 | (6.8) | 6 | 3.5 | 1.2 | 0.7 | |||
Nuclear grade | 1/2 | 17 | (38.6) | 7.4 | 3.6 | 0.06 | 1 | 0.2 | 0.007 |
3 | 21 | (47.7) | 10 | 4.7 | 1.4 | 0.5 | |||
Unknown | 6 | (13.6) | – |  |  | – | – |  | |
Nodal involvement | 0 | 12 | (27.2) | 6.8 | 3.3 | 0.01 | 1.2 | 0.4 | 0.9 |
≥ 1 | 32 | (72.7) | 10.5 | 4.6 | 1.2 | 0.4 | |||
ER | + | 26 | (59) | 9.1 | 4.2 | 0.7 | 1.1 | 0.3 | 0.04 |
– | 18 | (40.9) | 9.6 | 5.1 | 1.4 | 0.5 | |||
PgR | + | 19 | (43.1) | 7.9 | 3.1 | 0.07 | 1 | 0.2 | 0.009 |
– | 25 | (56.8) | 10.4 | 5.2 | 1.4 | 0.5 | |||
HER2 | + | 7 | (15.9) | 7.8 | 3.6 | 0.3 | 1.2 | 0.2 | 1 |
– | 37 | (84) | 9.6 | 4.7 | 1.2 | 0.4 | |||
Luminal A | Â | 7 | (15.9) | 7.8 | 2.5 | 0.4 | 0.9 | 0.2 | 0.03 |
Luminal B | Â | 16 | (36.4) | 9.7 | 4.8 | 1.1 | 0.3 | ||
TNBC | Â | 14 | (31.8) | 10.5 | 5.4 | 1.4 | 0.5 | ||
HER2 | Â | 7 | (15.9) | 7.9 | 3.6 | 1.2 | 0.2 | ||
Chemotherapy | + | 39 | (88.6) | 9.7 | 4.6 | 0.1 | 1.2 | 0.4 | 0.01 |
– | 5 | (11.4) | 6.4 | 3 | 0.7 | 0.1 | |||
Endocrine therapy | + | 26 | (59) | 9.1 | 4.2 | 0.7 | 1.1 | 0.3 | 0.04 |
– | 18 | (40.9) | 9.6 | 5.1 | 1.4 | 0.5 |